AUPP437698A0 - Methods for treatment of coronary, carotid and other vascular disease - Google Patents

Methods for treatment of coronary, carotid and other vascular disease

Info

Publication number
AUPP437698A0
AUPP437698A0 AUPP4376A AUPP437698A AUPP437698A0 AU PP437698 A0 AUPP437698 A0 AU PP437698A0 AU PP4376 A AUPP4376 A AU PP4376A AU PP437698 A AUPP437698 A AU PP437698A AU PP437698 A0 AUPP437698 A0 AU PP437698A0
Authority
AU
Australia
Prior art keywords
treatment
methods
carotid
coronary
vascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP4376A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baumgart Karl
Original Assignee
Baumgart Karl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baumgart Karl filed Critical Baumgart Karl
Priority to AUPP4376A priority Critical patent/AUPP437698A0/en
Publication of AUPP437698A0 publication Critical patent/AUPP437698A0/en
Priority to US09/736,029 priority patent/US6475518B1/en
Priority to CA2684402A priority patent/CA2684402C/en
Priority to DE69934010T priority patent/DE69934010T2/de
Priority to ES06023648.6T priority patent/ES2514469T3/es
Priority to AU45919/99A priority patent/AU757293B2/en
Priority to AT99928901T priority patent/ATE345115T1/de
Priority to CA2336593A priority patent/CA2336593C/en
Priority to PCT/AU1999/000528 priority patent/WO2000001378A1/en
Priority to HK01107443.7A priority patent/HK1037864B/en
Priority to EP06023648.6A priority patent/EP1754472B1/en
Priority to NZ509504A priority patent/NZ509504A/en
Priority to ES99928901T priority patent/ES2278449T3/es
Priority to JP2000557825A priority patent/JP4651816B2/ja
Priority to EP99928901A priority patent/EP1093363B1/en
Priority to JP2010074109A priority patent/JP5335726B2/ja
Priority to JP2013076511A priority patent/JP2013147504A/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AUPP4376A 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease Abandoned AUPP437698A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease
US09/736,029 US6475518B1 (en) 1998-06-30 1999-06-20 Methods and compositions for treatment of disorders associated with chlamydia and similar bacterial infection
EP99928901A EP1093363B1 (en) 1998-06-30 1999-06-30 Compositions for treatment of disorders associated with chlamydia
PCT/AU1999/000528 WO2000001378A1 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
HK01107443.7A HK1037864B (en) 1998-06-30 1999-06-30 Compositions for treatment of disorders associated with chlamydia
ES06023648.6T ES2514469T3 (es) 1998-06-30 1999-06-30 Composiciones para el tratamiento de trastornos asociados con Chlamydia
AU45919/99A AU757293B2 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
AT99928901T ATE345115T1 (de) 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
CA2336593A CA2336593C (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
CA2684402A CA2684402C (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection
DE69934010T DE69934010T2 (de) 1998-06-30 1999-06-30 Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
EP06023648.6A EP1754472B1 (en) 1998-06-30 1999-06-30 Compositions for treatment of disorders associated with chlamydia
NZ509504A NZ509504A (en) 1998-06-30 1999-06-30 Combination antibiotics for treatment of disorders associated with chlamydial and similar bacterial infection
ES99928901T ES2278449T3 (es) 1998-06-30 1999-06-30 Composiciones para el tratamiento de trastornos asociados a la chlamydia.
JP2000557825A JP4651816B2 (ja) 1998-06-30 1999-06-30 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2010074109A JP5335726B2 (ja) 1998-06-30 2010-03-29 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
JP2013076511A JP2013147504A (ja) 1998-06-30 2013-04-02 クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP4376A AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease

Publications (1)

Publication Number Publication Date
AUPP437698A0 true AUPP437698A0 (en) 1998-07-23

Family

ID=3808619

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPP4376A Abandoned AUPP437698A0 (en) 1998-06-30 1998-06-30 Methods for treatment of coronary, carotid and other vascular disease
AU45919/99A Expired AU757293B2 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU45919/99A Expired AU757293B2 (en) 1998-06-30 1999-06-30 Methods and compositions for treatment of disorders associated with chlamydial and similar bacterial infection

Country Status (10)

Country Link
US (1) US6475518B1 (https=)
EP (2) EP1754472B1 (https=)
JP (3) JP4651816B2 (https=)
AT (1) ATE345115T1 (https=)
AU (2) AUPP437698A0 (https=)
CA (2) CA2684402C (https=)
DE (1) DE69934010T2 (https=)
ES (2) ES2514469T3 (https=)
NZ (1) NZ509504A (https=)
WO (1) WO2000001378A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6756369B2 (en) * 1997-05-06 2004-06-29 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
AU3760400A (en) * 1999-03-19 2000-10-09 Vanderbilt University Methods and reagents for the diagnosis and treatment of multiple sclerosis
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6623757B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Antibiotic composition
ES2312422T3 (es) * 2000-03-22 2009-03-01 PHARMACIA & UPJOHN COMPANY LLC Formulacion de comprimido de oxazolidinona.
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
IT1318459B1 (it) 2000-04-11 2003-08-25 Zambon Spa Uso del tiamfenicolo e di suoi derivati per la preparazione dicomposizioni farmaceutiche utili per il trattamento di infezioni da
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
EP1262185A1 (en) * 2001-05-30 2002-12-04 New Pharma Research Sweden AB Synergistic antibiotic compositions
WO2003004098A1 (en) * 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
EP1531828A4 (en) * 2002-05-23 2005-11-02 Activbiotics Inc METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES
US20090149453A1 (en) * 2002-05-23 2009-06-11 Activbiotics Pharma Llc Methods and compositions for treating bacterial infections and diseases associated therewith
US20040077533A1 (en) * 2002-05-23 2004-04-22 Sayada Chalom B. Methods and compositions for treating bacterial infections and diseases associated therewith
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
EP1575567A4 (en) * 2002-12-12 2008-10-08 Activbiotics Inc METHOD AND REAGENTS FOR TREATING OR PREVENTING ATHEROSCLEROSIS AND DISEASES ASSOCIATED WITH IT
US20040126414A1 (en) * 2002-12-12 2004-07-01 Michaelis Arthur F. Methods and compositions for treating and preventing ear infections
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
RU2254123C2 (ru) * 2003-08-11 2005-06-20 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) Препарат для лечения гемобартонеллеза кошек и способ его применения
WO2005027961A2 (en) * 2003-09-23 2005-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Chlamydia pmpd autotransporter and its role as adhesin
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US20110097402A1 (en) * 2004-09-30 2011-04-28 Covalon Technologies Inc. Non-adhesive elastic gelatin matrices
WO2006057429A1 (ja) * 2004-11-24 2006-06-01 Nanocarrier Co., Ltd. ブロックコポリマーのモーフォロジ－の変化方法
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007025146A2 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
FR2891744B1 (fr) * 2005-10-06 2009-10-09 France Etat Armement Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline
WO2009015214A2 (en) * 2007-07-24 2009-01-29 Wayne State University Nanoparticles for imaging and treating chlamydial infection
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
DE112010004110T8 (de) 2009-10-22 2012-12-06 Thomas Julius Borody Neue parasitentherapie
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2563117B1 (en) 2010-04-26 2018-02-21 Salix Pharmaceuticals, Ltd. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
WO2013025105A1 (en) * 2011-08-16 2013-02-21 /Purac Biochem B.V. Recovery of carboxylic acid from their magnesium salts by precipitation using hydrochloric acid, useful for fermentation broth work-up
HUE043852T2 (hu) 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CA2997671A1 (en) * 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
RU2020102908A (ru) 2017-06-26 2021-07-27 Лунелла Байотек, Инк. Митокетосцины: митохондриальная терапия, нацеленная на кетоновый метаболизм в раковых клетках
WO2019148249A1 (en) * 2018-02-01 2019-08-08 Centre For Digestive Diseases Compositions for treating infective arterial diseases and related conditions
RU2684728C1 (ru) * 2018-05-21 2019-04-12 федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" Препарат на основе пчелиного маточного молочка для лечения мелких домашних животных при гемобартонеллезе
CN115867288A (zh) * 2020-03-27 2023-03-28 维克多瑞有限公司 用于治疗呼吸系统病症的组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588550A (en) 1897-08-24 Alarm-clock
GB1463550A (en) 1974-08-06 1977-02-02 Bodrero G Pharmaceutical composition
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI883067A7 (fi) * 1988-06-27 1989-12-28 Labsystems Oy Foerfarande foer behandling av koronarkaerlsjukdom.
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US6080757A (en) * 1996-06-06 2000-06-27 Pfizer Inc Antibiotic quinolones and derivatives
US6838552B1 (en) * 1997-08-14 2005-01-04 Vanderbilt University Diagnosis and management of infection caused by Chlamydia
US5811121A (en) 1997-01-29 1998-09-22 Eastman Chemical Company PH-sensitive coatings based on cellulose acetoacetate
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物

Also Published As

Publication number Publication date
JP4651816B2 (ja) 2011-03-16
JP2002519374A (ja) 2002-07-02
ES2514469T3 (es) 2014-10-28
JP2013147504A (ja) 2013-08-01
CA2684402C (en) 2012-10-30
AU4591999A (en) 2000-01-24
EP1754472A3 (en) 2009-08-26
EP1093363A4 (en) 2003-09-24
ATE345115T1 (de) 2006-12-15
HK1037864A1 (en) 2002-02-22
JP5335726B2 (ja) 2013-11-06
AU757293B2 (en) 2003-02-13
CA2336593A1 (en) 2000-01-13
JP2010174030A (ja) 2010-08-12
CA2684402A1 (en) 2000-01-13
EP1093363A1 (en) 2001-04-25
EP1754472A2 (en) 2007-02-21
ES2278449T3 (es) 2007-08-01
CA2336593C (en) 2010-06-29
DE69934010T2 (de) 2007-06-21
EP1754472B1 (en) 2014-07-23
NZ509504A (en) 2004-04-30
EP1093363B1 (en) 2006-11-15
WO2000001378A1 (en) 2000-01-13
US6475518B1 (en) 2002-11-05
DE69934010D1 (de) 2006-12-28

Similar Documents

Publication Publication Date Title
AUPP437698A0 (en) Methods for treatment of coronary, carotid and other vascular disease
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
CA2263972A1 (en) 6-o-substituted ketolides having antibacterial activity
IL183296A0 (en) Multivalent vaccine composition with mixed carrier
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
WO2000044761A3 (en) Ketolide antibiotics
PT1021456E (pt) Derivados macrociclicos de eritromicinas a e b de anel de 13 membros
CA2359354A1 (en) Medicament for the treatment, prevention and diagnosis of infection due to chlamydia pneumoniae
DE69631609D1 (en) Tricyclische erythromycinderivate
EP0932613A4 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
HUP0004579A2 (hu) Antibakteriális hatású, a 3'-N-pozícióban módosított szerkezetű 6-0-szubsztituált-eritromicin-ketolid-származékok és ezeket tartalmazó gyógyszerkészítmények
WO1998019670A3 (en) Combination therapy of hepatitis C infections
MX9708611A (es) Compuestos de dialquiltiacumicina.
DK1007530T3 (da) 6-O-substituerede erythromycinforbindelser samt fremgangsmåde til fremstilling heraf
CA2380455A1 (en) 9a-azalides with antibacterial activity
ID25478A (id) Agonis 5-ht1f
WO2000010998A3 (en) Pyridone antibiotic with improved safety profile
ZA971036B (en) Pharmaceutical compositions for the prevention or treatment of retrovirus infections.
WO2002057281A3 (en) Aminoglycosides as antibiotics
WO1998014567A3 (en) Methods and compositions for inhibiting bacterial growth
CA2564020A1 (en) 6-o-substituted ketolides having antibacterial activity
ES2191778T3 (es) Derivados de 3-desoxi-3-descladinosa de las eritromicinas a y b.
SE9902673D0 (sv) New composition
WO2001047522A3 (fr) Association de deoxyfructosazine et d'un antidiabetique de la famille des biguanides

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 4591999

Country of ref document: AU